InvestorsHub Logo
Followers 11
Posts 197
Boards Moderated 0
Alias Born 08/29/2013

Re: None

Monday, 10/05/2015 7:41:48 AM

Monday, October 05, 2015 7:41:48 AM

Post# of 124
Positive Trial Three Data Announced

On October 5, 2015, Spark Therapeutics, Inc. (the “Company”) issued a press release announcing the top-line results of its pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCE News